Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma

키워드

참고문헌 (7)

1. Finn RS, "IMbrave150 : a randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma", J Clin Oncol, 36(15) (2018)
2. Gordan JD, "Systemic therapy for advanced hepatocellular carcinoma : ASCO guideline", J Clin Oncol, 38, pp.4317~4345 (2020)
3. Kudo M, "Management of hepatocellular carcinoma in Japan : JSH consensus statements and recommendations 2021 update", Liver cancer, 10, pp.181~223 (2021)
4. Iwamoto H, "Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real-world clinical practice", Cancers(Basel), 13, pp.2786~ (2021)
5. Kudo M, "Objective response by mRECIST is an independent prognostic factor for overall survival in hepatocellular carcinoma treated with sorafenib in the SILIUS Trial", Liver Cancer, 8, pp.505~519 (2019)
6. Llovet JM, "mRECIST for HCC : performance and novel refinements", J Hepatol, 72, pp.288~306 (2020)
7. Ando Y, "Early tumor response and safety of atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma in real-world practice", Cancers(Basel), 13, pp.3958~ (2021)

관련 논문AI추천